The impact of hospice on end-of-life expenditures and total cost of care in episodic value-based care models at a community oncology network.

Authors

null

Gunjan Sharma

The US Oncology Network, Woodlands, TX

Gunjan Sharma, Divya Deepak, Jessica Neeb, Jody S. Garey, Hope Ives Thomas, Lydia Mills, Judi Payne-De Bock, Lalan S. Wilfong, Puneeth Indurlal

Organizations

The US Oncology Network, Woodlands, TX, The US Oncology Network, The Woodlands, TX, The US Oncology Network, McKesson, The Woodlands, TX, McKesson Specialty Health, Spring, TX, US Oncology Network, Dallas, TX

Research Funding

No funding received
None.

Background: The Institute of Medicine highlighted that multiple care transitions and fragmented care delivery at the end-of-life (EOL) is a burden to patients and caregivers. Hospice care has been shown to deliver high-quality, coordinated, and comprehensive EOL care while reducing unneeded healthcare interventions and improving EOL patient experience (preference of place of death, type of EOL care). The impact of timely hospice care on Total Cost of Care (TCOC) in episodic value-based care (VBC) models and patient experience at the EOL is largely unknown. The Oncology Care Model (OCM) was a 6-year long Medicare VBC program that encouraged care transformation at Oncology practices to drive better quality of care and patient experience, while decreasing TCOC. We studied the impact of timely hospice enrollment on TCOC, EOL expenditures, and patient experience. Methods: We obtained episode level data for patients who died in an episode (decedents) during the 6-years of the OCM (July 2016 to June 2022), for 15 practices in The US Oncology Network (The Network) participating in the OCM, along with several expenditure, clinical and episodic characteristics. We evaluated utilization and experience outcomes for episodes with and without hospice. Results: Of the 26,074 decedents during the 6-year period of the OCM, 55% were enrolled in hospice for 3 or more days (Hsp), and 45% were not enrolled or enrolled in hospice for less than 3 days (NoHsp). Mean TCOC for Hsp episodes ($41,297, n = 14,240) was significantly lower (Mann Whitney U test, p-value < 0.0001, significance level = 0.01) than NoHsp ($47,601, n = 11,834) episodes. TCOC comparison by expense cohort results are provided in Table 1. Median duration of hospice for Hsp episodes was 9 days. Mean ICU and inpatient spend in last 30 days of life in NoHsp group was more than 2 times the spend in Hsp group. 44% of patients in NoHsp group died in a hospital or an ICU setting, whereas 97% of patients in Hsp group died at home or in a hospice setting. Conclusions: Patients enrolled in hospice for 3 or more days had lower EOL care expenditures, fewer acute care interventions, and died at home or in hospice. Timely and proactive enrollment in hospice and coordinated EOL care can improve patient experience, but also reduce EOL costs for the healthcare system and patients. CMMI Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.

Total cost of care comparison results.
Measure Name (Mean expense)Hsp (n = 14240)
Mean
NoHsp (n = 11834)
Mean
P-value
All services per episode$41,297$47,601< 0.0001
All services in last 30 days of life$11,899$22,228< 0.0001
ICU in last 30 days of life$9,739$19,780< 0.0001
Inpatient use in last 30 days of life$5,552$13,700< 0.0001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care

Sub Track

End-of-Life Care

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 228)

DOI

10.1200/OP.2023.19.11_suppl.228

Abstract #

228

Poster Bd #

G9

Abstract Disclosures

Similar Abstracts

First Author: Shitanshu Uppal

First Author: Anshu Hemrajani

First Author: Adil Jamal Akhtar

First Author: Amy Foster